Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Idogen AB

Home Clinical Trial Sponsors and OrganizationsIdogen AB

Idogen AB

ACTIVE

Swedenwww.idogen.sePublic10 employeesEstablished: 2008-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

2

2 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

2

100.0%

Trial Status Distribution

Active, not recruiting

2

100.0%

Clinical Trials

Trials sponsored by this organization (2)

This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)

Active, not recruiting

Oct 20226 participants

This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance.

Active, not recruiting

Jan 20229 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials2
Approvals
News

Back to Organizations